These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 7436702)

  • 1. [Value of DNFB skin testing in patients with bladder cancer (author's transl)].
    Hudemann B; Seyfarth M
    Arch Geschwulstforsch; 1980; 50(2):173-7. PubMed ID: 7436702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [DNFB reaction in bladder cancer, an immunological study].
    Hudemann B; Günther M; Seyfarth M
    Z Urol Nephrol; 1979 Oct; 72(10):729-32. PubMed ID: 532391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The prognostic significance of the immune status (DNCB-test) in patients with carcinoma of the bladder, checked by observation of the course of disease (author's transl)].
    Flamm J; Burkert S
    Wien Med Wochenschr; 1981; 131(13-14):339-43. PubMed ID: 7281701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of 1-fluoro-2,4-dinitrobenzene as an affinity label for the antigen receptor of delayed hypersensitivity.
    Godfrey HP
    Immunology; 1976 Oct; 31(4):665-73. PubMed ID: 789233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Skin testing in genitourinary carcinoma: 2-year followup.
    Decenzo JM; Allison R; Leadbetter GW
    J Urol; 1975 Aug; 114(2):271-3. PubMed ID: 1171996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Influence of T-lymphocytes in bladder cancer on appearance and infiltration of recurrences (author's transl)].
    Stöber U
    Urologe A; 1978 Sep; 17(5):296-302. PubMed ID: 309205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topical induction of delayed hypersensitivity in the bladder.
    Burke C; Kumar V; Olsson CA
    Invest Urol; 1979 May; 16(6):421-7. PubMed ID: 447475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The immunologic behavior of carcinoma in situ of the bladder].
    Hudemann B; Riedel H; Seyfarth M; Werner H; Erdmann T
    Z Urol Nephrol; 1982 Apr; 75(4):253-7. PubMed ID: 7102136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNCB and PPD skin testing in breast cancer.
    Munzarová M; Kovarík J; Ninger E; Zemanová D; Lauerová L; Kolcová V; Hlávková J; Pacovský Z
    Neoplasma; 1983; 30(4):385-9. PubMed ID: 6888607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Use of a human embryonic antigen complex in studying the immune response in cancer patients].
    Gorodilova VV; Mandrik EV; Ul'chenko VM
    Vopr Onkol; 1982; 28(1):23-7. PubMed ID: 7199781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of soluble Fas in the serum of patients with bladder cancer.
    Mizutani Y; Yoshida O; Bonavida B
    J Urol; 1998 Aug; 160(2):571-6. PubMed ID: 9679930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cellular immune reactions in patients with malignant tumors: correlation of phytohemagglutinin-induced lymphocyte transformation and epicutanous tests using dinitrofluorobenzene].
    Schwarze G; Pappas A
    Verh Dtsch Ges Inn Med; 1976; 82 Pt 2():1852-4. PubMed ID: 1030123
    [No Abstract]   [Full Text] [Related]  

  • 13. Association of positive serum anti-p53 antibodies with poor prognosis in bladder cancer patients.
    Gumus E; Erdamar S; Demirel G; Horasanli K; Kendirci M; Miroglu C
    Int J Urol; 2004 Dec; 11(12):1070-7. PubMed ID: 15663677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Quantification of bladder tumor antigen (BTA trak) and its correlation with bladder cancer grade and stage].
    Rodríguez Martínez JJ; Escaf Barmadah S; Allende MT; Raigoso P; Martín Benito JL; Pérez García FJ; Fernández Gómez JM
    Arch Esp Urol; 2000; 53(1):1-6. PubMed ID: 10730418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Results of radical cystectomy for management of invasive bladder cancer with special reference to prognostic factors and quality of life depending on the type of urinary diversion].
    Słojewski M
    Ann Acad Med Stetin; 2000; 46():217-29. PubMed ID: 11712306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Methyl heptine carbonate skin test in lung cancer--correlation with stage and prognosis].
    Takanami I; Nakayama H; Ishihara T; Yanai N
    Gan No Rinsho; 1984 Apr; 30(4):340-3. PubMed ID: 6727035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Host immunocompetence in genitourinary cancer: relation to tumor stage and prognosis.
    Catalona WJ; Tarpley JL; Potvin C; Chretien PB
    Natl Cancer Inst Monogr; 1978 Dec; (49):105-10. PubMed ID: 311891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SPECIFICITY OF PASSIVELY TRANSFERRED DELAYED HYPERSENSITIVITY.
    NAJARIAN JS; FELDMAN JD
    J Exp Med; 1963 Sep; 118(3):341-52. PubMed ID: 14077995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cutaneous response to dinitrochlorobenzene in patients with genito-urinary cancers.
    Duclos H; Schwarzenberg L; Duclos SH; Hugues H; Kuss R
    Biomedicine; 1977 Jan; 27(1):43-7. PubMed ID: 856314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of skin testing with dinitrochlorobenzene in patients with head and neck cancer.
    Osoba D; Kersey PA; Clark RM; Rosen IB
    Can J Surg; 1980 Jan; 23(1):43-4. PubMed ID: 7363157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.